P-013

P-013 is an investigational drug candidate being developed by Pangea Pharmaceuticals for the treatment of bacterial infections. Pangea Pharmaceuticals is a specialty pharmaceutical company that focuses on the development of reformulated and generic products, suggesting that P-013 is likely a new formulation or a generic version of an established antimicrobial agent. Specific details regarding its chemical composition, molecular target, and clinical development phase are currently not publicly available in the company's pipeline documentation, although it is listed as a pipeline candidate with an estimated launch date.